{"altmetric_id":7131531,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Pearl Therapeutics, Inc."],"first_seen_on":"2016-05-03T19:40:53+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1462296654,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01854645?term=PINNACLE+1&rank=1"],"nct_id":"NCT01854645","pubdate":"2013-05-13T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7644999,"mean":6.5733031223765,"rank":1051233,"this_scored_higher_than_pct":85,"this_scored_higher_than":6525754,"rank_type":"exact","sample_size":7644999,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":266342,"mean":11.386863832455,"rank":53703,"this_scored_higher_than_pct":78,"this_scored_higher_than":208883,"rank_type":"exact","sample_size":266342,"percentile":78},"this_journal":{"total_number_of_other_articles":20471,"mean":10.072981631656,"rank":3345,"this_scored_higher_than_pct":75,"this_scored_higher_than":15403,"rank_type":"exact","sample_size":20471,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":928,"mean":12.48917583603,"rank":107,"this_scored_higher_than_pct":76,"this_scored_higher_than":710,"rank_type":"exact","sample_size":928,"percentile":76}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["lung_disease_news"],"posts_count":1}},"posts":{"news":[{"title":"FDA Approves COPD Treatment Bevespi Aerosphere, a Long-acting Dual Bronchodilator - Lung Disease News","url":"http:\/\/lungdiseasenews.com\/2016\/05\/03\/fda-approves-copd-treatment-bevespi-aerosphere-long-acting-dual-bronchodilator\/","license":"public","citation_ids":[7131531,7131534,7131536],"posted_on":"2016-05-03T17:30:54+00:00","summary":"The U.S. FDA has approval AstraZeneca\u2019s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) for long-term maintenance treatment of airflow obstruction in patients suffering from chronic obstructive pulmonary disease (COPD), including\u2026","author":{"name":"Lung Disease News","url":"http:\/\/lungdiseasenews.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/172\/normal\/Screen_Shot_2014-10-02_at_10.51.31.png?1412243510"}}]}}